Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00635154 · ClinicalTrials.gov registry record · Phase 2
Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00635154: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT00635154 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00635154, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
RATIONALE: Some cancers need growth factors which are made by the body's white blood cells to keep growing.Anakinra may interfere with the growth factor and stop multiple myeloma from growing. Dexamethasone may stop cancer cells from growing. Giving anakinra together with dexamethasone may be an effective treatment for multiple myeloma. PURPOSE: This phase II trial is studying how well anakinra works when given with or without dexamethasone in treating patients with smoldering myeloma or indolent multiple myeloma.
Interventions
- BIOLOGICAL Anakinra (IL-1Ra)
- DRUG Dexamethasone acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2002-12 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00635154
The ClinicalTrials.gov registry entry for NCT00635154 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Anakinra (IL-1Ra) is the first listed.
NCT00635154 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00635154 about?
NCT00635154 is a clinical study titled "Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma". RATIONALE: Some cancers need growth factors which are made by the body's white blood cells to keep growing.Anakinra may interfere with the growth factor and stop multiple myeloma from growing. Dexamethasone may stop cancer cells from growing. Giving anakinra together with dexamethasone may be an eff...
What is the current status of trial NCT00635154?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2002-12. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00635154?
The interventions under investigation include: Anakinra (IL-1Ra) (BIOLOGICAL), Dexamethasone acetate (DRUG).
Who is sponsoring clinical trial NCT00635154?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.